Publications by authors named "S Bujarski"

Despite major therapeutic advancements in recent years, multiple myeloma (MM) remains an incurable disease with nearly all patients experiencing relapsed and refractory disease over the course of treatment. Extending the duration and durability of clinical responses will necessitate the development of therapeutics with novel targets that are capable of robustly and specifically eliminating myeloma cells. B-cell maturation antigen (BCMA) is a membrane-bound protein expressed predominantly on malignant plasma cells and has recently been the target of several novel therapeutics to treat MM patients.

View Article and Find Full Text PDF

Introduction: Multiple myeloma (MM) is an incurable bone marrow (BM)-based cancer involving clonal plasma cells. Most patients show elevated levels of serum monoclonal protein (sMP) and kappa or lambda serum free light chains (sFLCs) at diagnosis. However, around 1-2% of patients, termed nonsecretory, do not produce these biomarkers.

View Article and Find Full Text PDF

Refining clinical trial methodology has become increasingly important as study design is shown to influence treatment efficacy. To maximize the efficiency of randomized clinical trials (RCTs), researchers aim to establish standardized practices. The goal of this systematic review is to describe methodological practices of clinical trials for alcohol use disorder (AUD) over the past 40 years.

View Article and Find Full Text PDF
Article Synopsis
  • Ruxolitinib (RUX) is an FDA-approved medication for treating conditions like myelofibrosis and polycythemia vera, and this study examines its effectiveness combined with lenalidomide (LEN) in patients with progressing multiple myeloma who previously received other treatments.
  • The study involved a phase I trial where participants, after failing initial therapies, received a combination of RUX and methylprednisolone (MP), and those with disease progression were given LEN as well.
  • Of the 29 participants, there was a 31% overall response rate to the initial RUX and MP treatment, with some showing varying degrees of disease stabilization, but also highlighted the challenges in managing advanced
View Article and Find Full Text PDF

The Letter to the Editors regarding our article was reviewed. The take-home message is that substantively, the authors of the letter are referencing a paper that asks a different research question in a different set of studies. When we ask different questions, we are not surprised when we reach different answers.

View Article and Find Full Text PDF